120 related articles for article (PubMed ID: 34782424)
21. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
[TBL] [Abstract][Full Text] [Related]
22. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
Sauter G; Steurer S; Clauditz TS; Krech T; Wittmer C; Lutz F; Lennartz M; Janssen T; Hakimi N; Simon R; von Petersdorff-Campen M; Jacobsen F; von Loga K; Wilczak W; Minner S; Tsourlakis MC; Chirico V; Haese A; Heinzer H; Beyer B; Graefen M; Michl U; Salomon G; Steuber T; Budäus LH; Hekeler E; Malsy-Mink J; Kutzera S; Fraune C; Göbel C; Huland H; Schlomm T
Eur Urol; 2016 Apr; 69(4):592-598. PubMed ID: 26542947
[TBL] [Abstract][Full Text] [Related]
23. Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index.
Stephan C; Lein M; Matalon J; Kilic E; Zhao Z; Busch J; Jung K
J Urol; 2016 Sep; 196(3):709-14. PubMed ID: 26976204
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
25. Clinical Utility of 4Kscore
de la Calle CM; Fasulo V; Cowan JE; Lonergan PE; Maggi M; Gadzinski AJ; Yeung RA; Saita A; Cooperberg MR; Shinohara K; Carroll PR; Nguyen HG
J Urol; 2021 Feb; 205(2):452-460. PubMed ID: 32897802
[TBL] [Abstract][Full Text] [Related]
26. The quantitative Gleason score improves prostate cancer risk assessment.
Reese AC; Cowan JE; Brajtbord JS; Harris CR; Carroll PR; Cooperberg MR
Cancer; 2012 Dec; 118(24):6046-54. PubMed ID: 22674220
[TBL] [Abstract][Full Text] [Related]
27. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
Stroup SP; Moreira DM; Chen Z; Howard L; Berger JH; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
J Urol; 2017 Dec; 198(6):1309-1315. PubMed ID: 28709888
[TBL] [Abstract][Full Text] [Related]
28. The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.
Dolejsova O; Kucera R; Fuchsova R; Topolcan O; Svobodova H; Hes O; Eret V; Pecen L; Hora M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818787377. PubMed ID: 30021484
[TBL] [Abstract][Full Text] [Related]
29. Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?
Abd-Alazeez M; Ahmed HU; Arya M; Allen C; Dikaios N; Freeman A; Emberton M; Kirkham A
Urol Oncol; 2014 Aug; 32(6):741-7. PubMed ID: 24981993
[TBL] [Abstract][Full Text] [Related]
30. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
31. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
32. Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies.
Barnett CL; Auffenberg GB; Cheng Z; Yang F; Wang J; Wei JT; Miller DC; Montie JE; Mamawala M; Denton BT
Cancer; 2018 Feb; 124(4):698-705. PubMed ID: 29131319
[TBL] [Abstract][Full Text] [Related]
33. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
34. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
Patel AA; Chen MH; Renshaw AA; D'Amico AV
JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
[TBL] [Abstract][Full Text] [Related]
35. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
Dietrich D; Hasinger O; Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Wernert N; Perner S; Freedland SJ; Corman JM; Ittmann MM; Lark AL; Madden JF; Hartmann A; Schatz P; Kristiansen G
J Mol Diagn; 2013 Mar; 15(2):270-9. PubMed ID: 23266319
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.
Gorday W; Sadrzadeh H; de Koning L; Naugler CT
Clin Biochem; 2015 Dec; 48(18):1230-4. PubMed ID: 26164541
[TBL] [Abstract][Full Text] [Related]
37. Circulating mRNA signature as a marker for high-risk prostate cancer.
Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Rogatto SR; Cólus IMS
Carcinogenesis; 2020 Apr; 41(2):139-145. PubMed ID: 31305891
[TBL] [Abstract][Full Text] [Related]
38. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
39. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.
Berg KD; Thomsen FB; Nerstrøm C; Røder MA; Iversen P; Toft BG; Vainer B; Brasso K
BJU Int; 2016 Jun; 117(6):883-9. PubMed ID: 26823232
[TBL] [Abstract][Full Text] [Related]
40. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
